Background {#Sec1}
==========

The rate of reintubation after pediatric cardiac surgery is about 6--9%, and it is associated with a high rate of mortality \[[@CR1], [@CR2]\]. Therefore, adequate respiratory support for postextubation acute respiratory failure (ARF) is important.

A high-flow nasal cannula (HFNC) is a respiratory support device that can deliver heated and humidified air and oxygen at a higher rate than the patient's inspiratory flow rate \[[@CR3]\]. It can provide precise fractional oxygen delivery and mild positive airway pressure, and it flushes the nasopharyngeal dead space, reducing airway resistance. Thus, an HFNC therapy reduces the patient's work of breathing \[[@CR4]--[@CR7]\].

An HFNC is widely used for treatment of respiratory failure in children with bronchiolitis \[[@CR8]--[@CR10]\]. However, there has been only one study on the use of an HFNC after pediatric cardiac surgery \[[@CR11]\]. There has been no report on the use of an HFNC for ARF after pediatric cardiac surgery. Hence, there is no information about the physiological effect of HFNC therapy on ARF after pediatric cardiac surgery. Our working hypothesis was that HFNC therapy for postextubation ARF after pediatric cardiac surgery improves hemodynamic and respiratory parameters.

Methods {#Sec2}
=======

Study design and patient population {#Sec3}
-----------------------------------

This was a prospective observational study. The study period was 1 year (January 1, 2014, to December 31, 2014). The study was conducted in a tertiary teaching hospital that had 865 beds including 8 beds in the pediatric cardiac ICU. The pediatric cardiac ICU has approximately 400 admissions per year. Children less than 48 months of age who had postextubation ARF after pediatric cardiac surgery were included. There was no exclusion criterion. The definition of ARF is given in Table [1](#Tab1){ref-type="table"}. We determined this definition by modifying the definition used in a previous report \[[@CR12]\]. The use of accessory respiratory muscle was defined as intercostal retractions, sternal retractions, thoraco-abdominal dissociation, or nasal flaring.Table 1Definition of postextubation acute respiratory failureTachypneaRR \>50 breaths per minute (\<1 year old)\
RR \>40 breaths per minute (1--4 year old)HypoxemiaSaO~2~ \<92% (total repair)\
SaO~2~ \<75% (palliative operation)HypercapniaPaCO~2~ \>50 mmHgIncreased work of breathingUsing accessory respiratory musclePostextubation acute respiratory failure is defined by at least one of the criteria*RR* respiratory rate, *PaCO* ~*2*~ partial pressure of arterial carbon dioxide

In this study, we included patients with non-cyanotic heart disease and patients with cyanotic heart disease. We categorized the patients by the type of heart physiology (serial circulation vs. single ventricle) and did subgroup analysis.

CPB management {#Sec4}
--------------

We routinely do continuous ultrafiltration during cardiopulmonary bypass (CPB) and also do modified ultrafiltration just after the patient has been weaned from CPB. Continuous ultrafiltration and modified ultrafiltration were performed for all of the patients in this study.

HFNC management {#Sec5}
---------------

HFNC (Optiflow; Fisher and Paykel Healthcare Ltd., Auckland, New Zealand) therapy was started immediately after diagnosis of postextubation ARF. The flow was commenced at 2 L/kg/min. The inspiratory oxygen fraction (F~I~O~2~) was set to achieve target oxygen saturation (total repair, \>92%; palliative operation, 75--85%). The temperature was set to 37° with a humidifier. The nasal cannula size was selected according to the weight and nasal size of the patient.

Measurements {#Sec6}
------------

The outcome was physiological impact of HFNC therapy on postextubation ARF after pediatric cardiac surgery. Data for age, body weight, gender, risk adjustment for congenital heart surgery (RACHS-1) category \[[@CR13]\], and diagnosis were collected prospectively. Bedside nurses collected data for respiratory rate (RR) and stored the data in an electronic healthcare record (EHR). Data for systolic blood pressure (SBP) and heart rate (HR) were stored in an EHR automatically by using an electrical system.

Oxygen saturation (SaO~2~), partial pressure of arterial carbon dioxide (PaCO~2~), and lactate were analyzed using a blood gas analysis apparatus (ABL 800, Radiometer Co., Copenhagen, Denmark), and these data were also stored in the EHR. Data collected just before starting HFNC therapy were used for pre-HFNC analysis, and data collected 1 h after starting HFNC therapy were used for post-HFNC analysis. We compared these hemodynamic and respiratory parameters in the pre-HFNC and post-HFNC periods.

Statistical analysis {#Sec7}
--------------------

A previous study showed that the standard deviation of children's RR was 15.4 \[[@CR14]\]. We determined that a sample of 20 children was required to show power of 0.8 with an alpha error of 0.05 to detect 10 breaths per minute difference.

Continuous data were expressed as medians and their interquartile range (IQR) because of non-normal distribution. Categorical data were expressed as percentages. The Wilcoxon signed-rank test was used to compare physiological data. *P* values less than 0.05 were considered statistically significant. All statistical analyses were performed using statistical software (JMP® 11, SAS Institute Inc., Cary, NC, USA).

Results {#Sec8}
=======

Baseline characteristics and cardiac diagnoses of the patients are shown in Table [2](#Tab2){ref-type="table"}. Twenty children were included in the study. The median age and body weight were 4.5 (2.3--14.0) months and 4.3 (3.1--7.1) kg, respectively. Major cardiac diagnoses of the patients were hypoplastic left heart syndrome, atrioventricular defect, and ventricular septal defect. The reasons for performing HFNC therapy are shown in Table [3](#Tab3){ref-type="table"}. The major reason for HFNC therapy was use of accessory respiratory muscle. The median settings of the HFNC were flow rate of 2.1 (1.6--3.3) L/kg/min and F~I~O~2~ of 0.55 (0.3-0.68). The median time to diagnosis of ARF after extubation was 4 (0.75--21) h.Table 2Patient baseline characteristicsBaseline characteristicsMedian (IQR)Age (month)4.5 (2.8--10.0)Body weight (kg)4.0 (2.9--6.8)Male gender (%)80RACHS-13 (2--3)Palliative operation (%)40Mechanical ventilation (hours)75 (9--288)Cardiac diagnosis*n* (%)HLHS5 (25)CAVSD4 (20)VSD3 (15)TOF2 (10)Others (SA/SV, TGA, DORV, TAPVR, IAA, TA)6 (30)Cause of acute respiratory failure*n* (%)Atelectasis5 (25)Heart failure/fluid overload4 (20)Uncontrolled airway secretion4 (20)Upper airway obstruction2 (10)Airway bleeding1 (5)Hypoventilation (due to sedative drugs)1 (5)Weak cough1 (5)Unclassified2 (10)Outcomes*n* (% or IQR)HFNC failure, *n* (%)1 (5)24 h reintubation, *n* (%)1 (5)ICU length of stay (days)11 (7.5--17)*IQR* interquartile range, *RACHS-1* risk adjustment for congenital heart surgery, *HLHS* hypoplastic left heart syndrome, *CAVSD* complete atrioventricular septal defect, *VSD* ventricular septal defect, *TOF* tetralogy of fallot, *SA/SV* single atrium/single ventricle, *TGA* transposition of great arteries, *DORV* double outlet right ventricle, *TAPVR* total anomalous pulmonary venous return, *IAA* interruption of aortic arch, *TA* tricuspid atresia, *HFNC* high-flow nasal cannula Table 3Numbers of patients met criteria for acute respiratory failureReason*n* (%)Tachypnea7 (35)Hypoxemia6 (30)Hypercapnia8 (40)Using accessory respiratory muscle20 (100)

Physiological outcome data are shown in Table [4](#Tab4){ref-type="table"}. Among the hemodynamic variables, SBP significantly decreased from 87.5 (77.8--103.5) to 76.0 (70.3--85.0) mmHg (*p* = 0.003) after the start of HFNC therapy. There was no remarkable change in HR or lactate. Among the respiratory variables, RR significantly decreased from 43.5 (32.0--54.8) to 28.5 (21.0--40.5) breaths per minute (*p* = 0.0008) after the start of HFNC therapy. PaCO~2~ dropped, but the difference was not significant (46.4 vs. 46.0 mmHg, *p* = 0.05). SaO~2~ did not change after the start of HFNC therapy (92.9 vs. 95.1%, *p* = 0.15). The median duration of HFNC therapy was 44.0 (23.0--79.3) h. One (5%) of the patients was reintubated. Reintubation was performed for respiratory and cardiac reasons. There was no adverse event caused by HFNC therapy.Table 4Hemodynamic and respiratory parameters before and after high-flow nasal cannula therapy (*n* = 20)ParametersPre-HFNCPost-HFNC*p* valueRR (breaths per minute)43.5 (32.0--54.8)28.5 (21.0--40.5)0.0008PaCO~2~ (mmHg)46.4 (41.1--55.9)46.0 (42.1--51.9)0.05SaO~2~ (%)92.9 (77.5--97.1)95.1 (3.0--98.9)0.15SBP (mmHg)87.5 (77.8--103.5)76.0 (70.3--85.0)0.003HR (beats per minute)143.5 (111.3--155.8)117.5 (109.5--143.0)0.34Lactate (mmol/l)1.1 (0.5--1.7)1.0 (0.8--1.5)0.21*HFNC* high-flow nasal cannula, *RR* respiratory rate, *PaCO* ~*2*~ partial pressure of arterial carbon dioxide, *SaO* ~*2*~ arterial oxygen saturation, *SBP* systolic blood pressure, *HR* heart rate

The results of subgroup analysis were shown in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. The single ventricle group included patients with hypoplastic left heart syndrome (*n* = 5), single atrium/single ventricle (*n* = 1), and tricuspid atresia (*n* = 1). In the single ventricle group, there were no significant differences in hemodynamics and respiratory parameters after the start of HFNC therapy. In the serial circulation group, RR and SBP dropped significantly after the start of HFNC therapy.Table 5Baseline characteristics of subgroupBaseline characteristicsSerial circulation group (*n* = 13)Single ventricle group (*n* = 7)Age (month)5 (1--7.5)4 (3--25)Body weight (kg)4.1 (3.6--6.7)5 (2.7--9.7)Male gender (%)10 (77)4 (57)RACHS-13 (2--3)3 (3--6)Mechanical ventilation (hours)112 (22--268)43 (16--119)*RACHS-1* risk adjustment for congenital heart surgery Table 6Subgroup analysis: hemodynamic and respiratory parameters before and after high-flow nasal cannula therapy for serial circulation group (*n* = 13) and single ventricle group (*n* = 7)Serial circulation group (*n* = 13)Single ventricle group (*n* = 7)ParametersPre-HFNCPost-HFNC*p* valuePre-HFNCPost-HFNC*p* valueRR (breaths per minute)43 (31.5--55)25 (20.5--35.5)0.00344 (32--55)34 (32--43)0.2PaCO~2~ (mmHg)45.7 (41.1--53.2)46.3 (42.7--48.2)0.250.4 (38.1--61)45.6 (38.6--57.7)0.3SaO~2~ (%)95.4 (92.2--98.9)98.7 (86.5--99.4)0.569.3 (58.1--88.6)80.6 (65.3--88.3)0.2SBP (mmHg)95 (77--105)76 (68.5--80)0.00785 (80--93)80 (71--91)0.3HR (beats per minute)150 (110--164)115 (108--130)0.08138 (112--147)143 (116--150)0.4Lactate (mmol/l)1.1 (0.5--1.6)0.9 (0.7--1.4)0.41.1 (1.0--2.9)1.1 (1.0--2.2)0.5*HFNC* high-flow nasal cannula, *RR* respiratory rate, *PaCO* ~*2*~ partial pressure of arterial carbon dioxide, *SaO* ~*2*~ arterial oxygen saturation, *SBP* systolic blood pressure, *HR* heart rate

Discussion {#Sec9}
==========

The results of this study are valuable since we selected patients who had needed respiratory support because of ARF. There has been no other study about HFNC therapy for ARF after pediatric cardiac surgery. In addition, positive pressure induced by HFNC therapy may be deleterious in this specific patient cohort. Therefore, we selected these patients as a study target group to investigate the physiological impact of the use of an HFNC. Therefore, this is the first study that provides information about the physiological impact of the use of an HFNC for patients with ARF after pediatric surgery. Our results showed that HFNC therapy for postextubation ARF after pediatric cardiac surgery decreased SBP and RR in mixed serial circulation patients and single ventricle patients. This might be a beneficial effect of HFNC therapy for postextubation ARF after pediatric cardiac surgery. All of the patients in this study used accessory respiratory muscle. In this situation, reduced RR contributed to the reduction of work of breathing. A decrease in SBP might be caused by an improved respiratory state, which may reduce sympathetic nerve activity.

On the other hand, PaCO~2~, SaO~2~, Lactate, and HR did not change significantly. Increased end-expiratory lung volume caused by positive end expiratory pressure could decrease CO~2~ clearance \[[@CR15]\]. However, the airway gas washout effect of HFNC therapy may improve PaCO~2~ \[[@CR16], [@CR17]\]. These opposite effects may be the reason for no significant difference in PaCO~2~. Subgroup analysis also showed that SaO~2~ was not improved in either the serial circulation group or single ventricle group. SaO~2~ could be influenced by gas exchange in the alveolus, pulmonary blood flow, and F~I~O~2~. Therefore, we could not provide a definitive conclusion about change of SaO~2~. Lactate represents adequate oxygen supply to peripheral tissues. Thus, lactate does not always have a direct relationship with respiratory state. That was the reason why there was no significant difference in lactate in either of the groups. In our study, HR showed a large variation. We guess this influenced our results of no significant difference in HR.

The subgroup analysis showed that the beneficial effect of HFNC therapy on RR was limited to serial circulation. However, these results of subgroup analysis were not powered for subgroup analysis and should be interpreted carefully. Thus, further study is needed to investigate the impact of HFNC therapy on single ventricle patients.

There has been one randomized controlled trial (RCT) using HFNC therapy after pediatric cardiac surgery. Testa et al. showed that the use of HFNC therapy improved partial pressure of arterial oxygen (PaO~2~) in children after cardiac surgery but that there was no impact on PaCO~2~ \[[@CR11]\]. Our results are concordant with their results, showing that HFNC therapy has no impact on PaCO~2~. However, their study targeted children without ARF. In this situation, some children might not need respiratory support. The results must therefore be interpreted carefully.

In previous studies, rates of reintubation after pediatric cardiac surgery were 6--9% \[[@CR1], [@CR2]\]. In our study, only one (5%) of the 20 patients was reintubated because of failure of HFNC therapy. Our patients were selected patients at risk of reintubation. Despite the selection of such patients, the reintubation rate was lower than that in past studies. Schibler et al. showed in their retrospective study that HFNC therapy might reduce the need for intubation in infants with bronchiolitis \[[@CR18]\]. Further study is needed to confirm the effectiveness of HFNC therapy for preventing reintubation after pediatric cardiac surgery.

Limitations {#Sec10}
-----------

This study has some limitations. Firstly, we compared hemodynamic and respiratory parameters before and after HFNC therapy in the same patients. There was no control group in this study. We cannot rule out the possibility of improvement in RR without HFNC therapy. ARF is a critical event for patients after pediatric cardiac surgery. HFNC therapy for ARF has been used in our daily practice. Therefore, it was not clinically practical and ethically permissible to set a control group. Thus, we carried out observational study instead of an RCT or crossover study. There have been no available data about the use of an HFNC therapy for ARF after pediatric surgery. Our results for selected patients may be valuable for a future RCT.

Secondly, we included patients with various conditions (age, cyanosis, type of operation), and our definition of ARF is specific in our institute. It is therefore difficult to generalize that HFNC therapy is beneficial for ARF after pediatric cardiac surgery.

Conclusions {#Sec11}
===========

In conclusion, HFNC therapy improves the respiratory state of patients with postextubation ARF after pediatric cardiac surgery by reducing RR. The HFNC may be a useful device in postextubation ARF after pediatric cardiac surgery.
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